Fluorescent in situ hybridization for human epidermal growth factor receptor 2 assessment in breast cancer: is it applicable as a primary test?
about
Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcomaHybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer.
P2860
Fluorescent in situ hybridization for human epidermal growth factor receptor 2 assessment in breast cancer: is it applicable as a primary test?
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Fluorescent in situ hybridizat ...... applicable as a primary test?
@en
Fluorescent in situ hybridizat ...... applicable as a primary test?
@nl
type
label
Fluorescent in situ hybridizat ...... applicable as a primary test?
@en
Fluorescent in situ hybridizat ...... applicable as a primary test?
@nl
prefLabel
Fluorescent in situ hybridizat ...... applicable as a primary test?
@en
Fluorescent in situ hybridizat ...... applicable as a primary test?
@nl
P2093
P356
P1476
Fluorescent in situ hybridizat ...... applicable as a primary test?
@en
P2093
Arnaldo Capelli
Ilaria Pennacchia
Vincenzo Arena
P304
e8; author reply e9-10
P356
10.1200/JCO.2009.23.2249
P407
P577
2009-05-26T00:00:00Z